FastWave Medical was supposed to be a classic American success story. The Minnesota based company designs cutting edge medical devices that break up dangerous calcium deposits in arteries, using electric shock waves inside tiny balloons. Its technology, called intravascular lithotripsy, aims to make it easier and safer to treat conditions like peripheral artery disease in the legs and coronary artery disease in the heart.

Instead of racing toward the market, FastWave is now fighting for its life. Its biggest backer is a Chinese company, Grand Pharmaceutical Group, and FastWave’s leaders say that partner has turned into its main obstacle. What began as a lucrative investment now looks, to them and to several lawmakers, like a textbook example of how Chinese firms can quietly box in a promising American startup and try to capture its technology.

“We have mostly U.S. based investors who are very optimistic about what we are building,” cofounder and chief executive Scott Nelson said. “And then you contrast that to this Chinese investor that has almost done everything it can to block our ability to continue to operate the company.”

Who FastWave Is And Why Its Technology Matters

FastWave was founded around 2020 and is headquartered in Brooklyn Park, Minnesota. Nelson, a longtime health technology executive, helped start the firm after regulators struck down some patent claims held by an earlier player in the intravascular lithotripsy field. That ruling opened the door for new competitors, and FastWave’s founding team believed they could build a better system.

The company’s Artero device uses a small balloon at the end of a catheter. When activated inside a clogged artery, it sends out powerful shock waves that crack hardened calcium and help restore blood flow. Doctors hope that approach can reduce amputations in patients with severe peripheral artery disease and improve outcomes for people with coronary artery disease that can lead to heart attacks.

FastWave has already run demanding early clinical trials in places like Mexico and Uzbekistan, working with local partners and specialists to meet U.S. style standards for data and safety. The team records every procedure, monitors every case, and designs its trials to support eventual approval by the Food and Drug Administration.

To finish the job, Nelson says the company needs another 25 million to 30 million dollars. That money would fund a major trial in peripheral artery disease and start a new trial in coronary artery disease. Without it, the company could run out of cash and shut down, leaving its technology stranded.

The Chinese Investor Who Turned Into A Roadblock

In 2021, FastWave received a 12 million dollar investment from Grand Pharmaceutical Group, a large health care company based in Wuhan, China, with more than ten thousand employees. The money funded FastWave’s Series A round and gave Grand a stake of roughly 40 percent in the company, two board seats, and an option to buy the startup in the future.

At first, the relationship seemed normal. Grand sat on the board, and the two sides talked about global opportunities. Then the tone shifted.

In 2022, Grand’s leaders asked FastWave to shift its focus. Instead of moving first toward U.S. approval, they wanted the startup to prioritize the Chinese market. Nelson’s team agreed and spent months building catheters and reworking its plans with the understanding that Grand would keep funding the company.

“We did that with their commitment to continue to capitalize the company,” Nelson recalled. After FastWave had spent millions of dollars to pivot toward China, Grand abruptly said it would not provide more funding. No clear explanation followed, and FastWave never shipped those catheters to China.

Around the same time, Grand began investing in a Chinese company called Jiangsu Zhenyi Medical Technology, which makes its own peripheral vascular shock wave system. A translated news release in China described plans for “in depth cooperation” on research, development, and production with that firm. Nelson says Grand never disclosed this partnership to FastWave.

What was supposed to be jet fuel for a young American company started to look, in his view, like poison.

FastWave Says Grand Is Blocking New Money

FastWave has managed to bring in more than 50 million dollars over time, and Nelson says new investors in the United States are eager to provide the next round of financing. The problem is not demand. The problem is consent.

Because Grand owns a large stake and has special rights from the original deal, FastWave needs its cooperation to close another major funding round and to file required paperwork with the U.S. government.

Nelson says Grand has refused to sign key documents for the next round, even after the company received multiple offers. At one point, he says Grand demanded a 150 million dollar payment in exchange for letting the financing move ahead. That demand effectively killed the deal.

On top of that, FastWave must now submit a filing to the Committee on Foreign Investment in the United States, known as CFIUS. The committee reviews foreign investments that might give adversaries access to critical American technologies. Normally, the foreign investor and the U.S. company file together. Nelson says Grand has not cooperated, which forces FastWave to try to move forward alone, an unusual and difficult step.

From Nelson’s perspective, this is not random behavior. “It has absolutely been intentional and part of a strategy,” he said. In his view, Grand is “essentially suffocating us,” blocking funding, and dragging out the regulatory process at the very moment the company needs capital to survive.

What Nelson Thinks The Strategy Really Is

FastWave has put its theory in writing to CFIUS. In a letter, the company argued that Grand’s actions look like an “elaborate scheme” to crush the business and gain control of its technology. The fear is not just losing a company. It is watching sensitive medical laser systems drift into the orbit of a Chinese competitor that is working on similar products.

Nelson warns that FastWave’s laser components could be repurposed for use in semiconductor manufacturing or even defense, which raises national security questions. By freezing FastWave’s fundraising and investing in a rival at the same time, Grand appears, in his eyes, to be shifting the center of gravity for this technology from the United States to China.

From that perspective, profit is not the main objective. The priority is to corner a strategic technology, move the core know how to Chinese controlled companies, and leave the American originator starved of capital.

Nelson says FastWave is prepared to take legal action if necessary, although he notes that lawsuits are expensive and slow, which is why many startups try to avoid them. Still, he describes Grand’s corporate governance behavior as so extreme that the company is ready to fight in court if that is what it takes to protect its technology and investors.

A Political And National Security Flashpoint

FastWave’s struggle has reached far beyond Minnesota. National security hawks in Washington see the case as another warning about China’s approach to American innovation.

Representative John Moolenaar of Michigan, who chairs the House Select Committee on the Chinese Communist Party, put it bluntly. FastWave’s experience is “yet another warning of China’s concerted strategy to steal American technology,” he said. His committee has urged CFIUS to pay close attention to the parts of FastWave’s system that rely on lasers and could have military or semiconductor uses.

Representative Kat Cammack of Florida has also written to the Treasury secretary, who chairs CFIUS, asking the committee to prioritize the case. Those letters arrived while CFIUS reviews were already backed up and the government shutdown had slowed many processes, adding more uncertainty for FastWave.

The fight over FastWave comes in a broader climate of concern. In recent years, prosecutors have indicted people for allegedly stealing medical imaging designs from Philips and transferring them to Chinese companies. A former Google engineer was charged with taking trade secrets to use in China. Congress has considered bills that would bar entities receiving federal funds from working with certain Chinese pharmaceutical firms.

Supporters of tougher rules argue that these examples add up to a pattern. In their view, Chinese companies often act as instruments of state strategy, using investments, partnerships, and joint ventures to gain access to critical technologies. Profit from a single deal matters less than ensuring that key capabilities can be controlled or replicated inside China.

Critics, Cautionary Voices, And A Divided Debate

Not everyone believes FastWave’s story proves the need for sweeping new restrictions. Some experts point out that FastWave chose to accept money from a Chinese investor. To them, this voluntary decision makes the case different from situations where companies were hacked or copied without any partnership.

Michael Sobolik, a senior fellow at the Hudson Institute, takes a tougher line on corporate responsibility. He argues that companies should not wait for Washington to rescue them from “Beijing’s predatory practices.” If U.S. firms fall for what he calls Trojan horse investment schemes, he says, “China shows no mercy.”

Legal specialists also warn that defending intellectual property is difficult. Tom Hipkins, a patent lawyer at the firm Fredrikson and Byron, says IP theft is a major problem that makes startups nervous about sharing information with potential investors. At the same time, he notes that litigation is expensive, which can discourage small companies from fighting back.

On the regulatory side, attorney Elizabeth Hodgson describes CFIUS as a key tool to keep adversaries away from critical technologies. She says the process normally requires detailed information from foreign investors, which is why unilateral filings are rare. Interacting with the U.S. government can also scare some foreign backers, which may help explain why they drag their feet when reviews begin.

All of this plays out against a political backdrop in which President Trump recently paused a broader crackdown on Chinese companies that had been labeled security threats as part of a trade truce. Critics of that pause worry that it opens more space for Chinese firms to maneuver. They say weak corporate security practices in the United States give China fresh chances to capture important inventions in areas like artificial intelligence and health care.

A Battle For Survival And A Warning For Others

For now, FastWave is still running trials, still refining its devices, and still trying to solve what Nelson calls a “regulatory puzzle” so new investors can come in. He has hired lobbyists with ties to the Trump administration and a former head of CFIUS to guide the company through Washington. He is also weighing legal options if political and regulatory pressure are not enough.

Time, however, is not on his side. Nelson has warned that if FastWave cannot raise new capital by the end of the year, he may have to shut the company down. In that scenario, the technology he and his team built could end up controlled by the very foreign investor they now see as their adversary.

To national security hawks, this is exactly how a predatory strategy works. A deep pocketed Chinese firm offers generous funding, gains board seats and special rights, pushes the company to spend heavily to meet its demands, then withholds further support, blocks new money, and backs a rival at home. The American startup is left gasping, and the strategic technology drifts toward Chinese control.

FastWave’s fight is not just about one company or one device. It is a warning to founders who think foreign cash is always a blessing, and to policymakers who underestimate how far China is willing to go to corner the market in critical technologies, even when short term profit takes a back seat to power.

ACZ Editor: Chinese companies have as their primary duty to serve the state. There is little doubt that they report to the CCP and this is part of their strategy. This could be the end of Fastwave, and the technology will very likely end up in China.